Skip to main content
Erschienen in: Reactions Weekly 1/2022

01.05.2022 | Case report

Tozinameran

Fulminant necrotising eosinophilic myocarditis: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Ameratunga R, et al. First Identified Case of Fatal Fulminant Necrotizing Eosinophilic Myocarditis Following the Initial Dose of the Pfizer-BioNTech mRNA COVID-19 Vaccine (BNT162b2, Comirnaty): an Extremely Rare Idiosyncratic Hypersensitivity Reaction. Journal of Clinical Immunology 42: 441-447, No. 3, Apr 2022. Available from: URL: http://doi.org/10.1007/s10875-021-01187-0 Ameratunga R, et al. First Identified Case of Fatal Fulminant Necrotizing Eosinophilic Myocarditis Following the Initial Dose of the Pfizer-BioNTech mRNA COVID-19 Vaccine (BNT162b2, Comirnaty): an Extremely Rare Idiosyncratic Hypersensitivity Reaction. Journal of Clinical Immunology 42: 441-447, No. 3, Apr 2022. Available from: URL: http://​doi.​org/​10.​1007/​s10875-021-01187-0
Metadaten
Titel
Tozinameran
Fulminant necrotising eosinophilic myocarditis: case report
Publikationsdatum
01.05.2022
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2022
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-022-15252-2

Weitere Artikel der Ausgabe 1/2022

Reactions Weekly 1/2022 Zur Ausgabe

Case report

Fluorouracil

Case report

Cabergoline

Case report

Clonazepam

Case report

Clofarabine